Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. … Read more
Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Net Assets
Latest net assets as of September 2025: CN¥1.53 Billion CNY
Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has net assets worth CN¥1.53 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.99 Billion) and total liabilities (CN¥2.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.53 Billion |
| % of Total Assets | 38.35% |
| Annual Growth Rate | 19.01% |
| 5-Year Change | -66.45% |
| 10-Year Change | 329.87% |
| Growth Volatility | 92.85 |
Luoxin Pharmaceuticals Group Stock Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2024)
The table below shows the annual net assets of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.46 Billion | -43.27% |
| 2023-12-31 | CN¥2.57 Billion | -22.20% |
| 2022-12-31 | CN¥3.31 Billion | -30.18% |
| 2021-12-31 | CN¥4.74 Billion | +8.86% |
| 2020-12-31 | CN¥4.35 Billion | +9.81% |
| 2019-12-31 | CN¥3.96 Billion | +335.41% |
| 2018-12-31 | CN¥909.89 Million | +20.64% |
| 2017-12-31 | CN¥754.19 Million | +8.00% |
| 2016-12-31 | CN¥698.33 Million | +105.70% |
| 2015-12-31 | CN¥339.50 Million | +7.62% |
| 2014-12-31 | CN¥315.46 Million | +25.43% |
| 2013-12-31 | CN¥251.50 Million | +22.36% |
| 2012-12-31 | CN¥205.54 Million | +35.34% |
| 2011-12-31 | CN¥151.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Luoxin Pharmaceuticals Group Stock Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 242.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.09 Billion | 78.68% |
| Other Comprehensive Income | CN¥43.92 Million | 3.18% |
| Other Components | CN¥341.05 Million | 24.67% |
| Total Equity | CN¥1.38 Billion | 100.00% |
Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Market Cap
The table below lists competitors of Luoxin Pharmaceuticals Group Stock Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bandwidth Inc
NASDAQ:BAND
|
$409.33 Million |
|
Zhangjiagang Freetrade Science and Technology Co Ltd
SHG:600794
|
$409.46 Million |
|
Alto Neuroscience, Inc.
NYSE:ANRO
|
$409.58 Million |
|
EQ Resources Ltd
AU:EQR
|
$409.76 Million |
|
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
|
$409.29 Million |
|
Soho House & Co Inc.
NYSE:SHCO
|
$409.12 Million |
|
Fubotv Inc
NYSE:FUBO
|
$409.09 Million |
|
HEALTHCARE TR.PFD SH DL25
F:4ON
|
$408.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Luoxin Pharmaceuticals Group Stock Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,469,901,453 to 1,382,277,279, a change of -1,087,624,174 (-44.0%).
- Net loss of 965,496,163 reduced equity.
- Dividend payments of 61,191,581 reduced retained earnings.
- Share repurchases of 99,998,598 reduced equity.
- Other comprehensive income increased equity by 3,244,237.
- Other factors increased equity by 35,817,931.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-965.50 Million | -69.85% |
| Dividends Paid | CN¥61.19 Million | -4.43% |
| Share Repurchases | CN¥100.00 Million | -7.23% |
| Other Comprehensive Income | CN¥3.24 Million | +0.23% |
| Other Changes | CN¥35.82 Million | +2.59% |
| Total Change | CN¥- | -44.04% |
Book Value vs Market Value Analysis
This analysis compares Luoxin Pharmaceuticals Group Stock Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.31x to 3.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.25 | CN¥4.81 | x |
| 2012-12-31 | CN¥0.34 | CN¥4.81 | x |
| 2013-12-31 | CN¥0.41 | CN¥4.81 | x |
| 2014-12-31 | CN¥1.23 | CN¥4.81 | x |
| 2015-12-31 | CN¥1.33 | CN¥4.81 | x |
| 2016-12-31 | CN¥2.25 | CN¥4.81 | x |
| 2017-12-31 | CN¥2.22 | CN¥4.81 | x |
| 2018-12-31 | CN¥0.85 | CN¥4.81 | x |
| 2019-12-31 | CN¥10.23 | CN¥4.81 | x |
| 2020-12-31 | CN¥2.77 | CN¥4.81 | x |
| 2021-12-31 | CN¥3.01 | CN¥4.81 | x |
| 2022-12-31 | CN¥2.23 | CN¥4.81 | x |
| 2023-12-31 | CN¥2.28 | CN¥4.81 | x |
| 2024-12-31 | CN¥1.29 | CN¥4.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Luoxin Pharmaceuticals Group Stock Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -36.47%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 3.14x
- Recent ROE (-69.85%) is below the historical average (3.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 21.41% | 7.68% | 1.56x | 1.79x | CN¥17.33 Million |
| 2012 | 26.11% | 11.31% | 1.27x | 1.81x | CN¥33.11 Million |
| 2013 | 18.28% | 9.69% | 1.31x | 1.44x | CN¥20.81 Million |
| 2014 | 20.28% | 11.90% | 1.20x | 1.42x | CN¥32.41 Million |
| 2015 | 24.09% | 14.00% | 1.06x | 1.62x | CN¥47.84 Million |
| 2016 | 14.37% | 15.75% | 0.78x | 1.16x | CN¥30.53 Million |
| 2017 | 15.36% | 13.99% | 0.92x | 1.19x | CN¥40.43 Million |
| 2018 | 12.24% | 11.90% | 0.67x | 1.54x | CN¥20.36 Million |
| 2019 | 17.23% | 8.35% | 1.02x | 2.03x | CN¥266.04 Million |
| 2020 | 7.94% | 5.26% | 0.79x | 1.91x | CN¥-83.35 Million |
| 2021 | 9.26% | 6.27% | 0.68x | 2.17x | CN¥-32.36 Million |
| 2022 | -39.63% | -35.07% | 0.44x | 2.55x | CN¥-1.58 Billion |
| 2023 | -26.77% | -27.97% | 0.46x | 2.07x | CN¥-908.13 Million |
| 2024 | -69.85% | -36.47% | 0.61x | 3.14x | CN¥-1.10 Billion |
Industry Comparison
This section compares Luoxin Pharmaceuticals Group Stock Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Luoxin Pharmaceuticals Group Stock Co Ltd (002793) | CN¥1.53 Billion | 21.41% | 1.61x | $409.31 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |